Symbols / NNVC $1.18 +1.72%

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

Price estimates from analyst targets and simple models.

Latest analyst rating changes

• Antiviral NV-387 heads to Phase II mpox trial with new gummy form - Stock Titan Wed, 11 Mar 2026 12
• 2 Small-Cap Biotechs That Could Reward Patient Investors - Yahoo Finance Fri, 12 Dec 2025 08
• MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides - ACCESS Newswire hu, 12 Feb 2026 08
• NanoViricides (NYSE American: NNVC) closes $6M offering; Series A/B warrant placement - Stock Titan Wed, 12 Nov 2025 08
• ImmunityBio’s Immunotherapy ANKTIVA Sparks Revenue Surge as Global Expansion Accelerates (IBRX, NNVC) - marketscreener.com ue, 10 Mar 2026 12
• NanoViricides closes $6M offering to fund operations - Proactive financial news hu, 13 Nov 2025 08
• symbol__ Stock Quote Price and Forecast - CNN ue, 26 Mar 2024 11
• What is the current Price Target and Forecast for NanoViricides (NNVC) - Zacks Investment Research Wed, 31 Aug 2022 14
• Measles cases surge as NanoViricides seeks orphan status for NV-387 - Stock Titan ue, 10 Feb 2026 08
• NNVC Stock: The COVID-19 Drug News That Has NanoViricides Rocketing Today - InvestorPlace ue, 02 Mar 2021 08
• Resistance Check: How do insiders feel about NNVC - Portfolio Growth Summary & Fast Entry High Yield Tips - baoquankhu1.vn Fri, 06 Mar 2026 15
• NNVC Stock Price and Chart — AMEX:NNVC - TradingView Fri, 21 Jul 2017 02
• Is NanoViricides Inc. (NNVC) the Best Nanotech Penny Stock to Invest In? - Yahoo Finance Fri, 14 Feb 2025 08
• Nanoviricides Stock Price Forecast. Should You Buy NNVC? - StockInvest.us hu, 03 Dec 2020 11
• NNVC Stock Price, Quote & Chart | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill ue, 28 Jan 2020 18

• Income Statement
• Balance Sheet
• Cash Flow

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

• 10-Q2026-02-17 View
• 8-K2025-11-26 View
• 8-K2025-11-14 View
• 10-Q2025-11-14 View
• 8-K2025-10-01 View
• 10-K2025-09-29 View
• 10-Q2025-05-15 View
• 10-Q2025-02-14 View
• 42025-01-28 View
• 8-K2024-12-12 View
• 10-Q2024-11-14 View
• 10-K2024-09-27 View
• 8-K2024-08-09 View
• 10-Q2024-05-15 View
• 8-K2024-04-05 View